OPTIMIZATION OF CLINICAL DOSE SCHEDULE TO MANAGE NEUTROPENIA: LEARNINGS FROM A SEMI-MECHANISTIC MODELING SIMULATION APPROACH.

被引：0
|
作者：
Guo, Y. [1 ]
Haddish-Berhane, N. [1 ]
Xie, H. [1 ]
Ouellet, D. [1 ]
机构：
[1] Janssen, Spring House, PA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PWI-001
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 6 条
  • [1] OPTIMIZATION OF CLINICAL DOSE SCHEDULE TO MANAGE NEUTROPENIA: LEARNINGS FROM A SEMI-MECHANISTIC MODELING SIMULATION APPROACH.
    Guo, Y.
    Haddish-Berhane, N.
    Xie, H.
    Ouellet, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S97 - S97
  • [2] Optimization of clinical dosing schedule to manage neutropenia: learnings from semi-mechanistic modeling simulation approach
    Yue Guo
    Nahor Haddish-Berhane
    Hong Xie
    Daniele Ouellet
    Journal of Pharmacokinetics and Pharmacodynamics, 2020, 47 : 47 - 58
  • [3] Optimization of clinical dosing schedule to manage neutropenia: learnings from semi-mechanistic modeling simulation approach
    Guo, Yue
    Haddish-Berhane, Nahor
    Xie, Hong
    Ouellet, Daniele
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2020, 47 (01) : 47 - 58
  • [4] Semi-Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA
    Meng, Amy
    Humeniuk, Rita
    Jurgensmeier, Juliane M.
    Hsueh, Chia-Hsiang
    Matzkies, Franziska
    Grant, Ethan
    Hoa Truong
    Billin, Andrew N.
    Yu, Helen
    Feng, Joy
    Kwan, Ellen
    Tarnowski, Thomas
    Nelson, Cara H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (02) : 416 - 424
  • [5] Dose Optimization of Aditoprim-Sulfamethoxazole Combinations Against Trueperella pyogenes From Patients With Clinical Endometritis by Using Semi-mechanistic PK/PD Model
    Maan, Muhammad Kashif
    Chaudhry, Tamoor Hamid
    Sattar, Adeel
    Shabbir, Muhammad Abu Bakr
    Ahmed, Saeed
    Mi, Kun
    Ahmed, Waqas
    Xie, Shuyu
    Xin, Li
    Huang, Lingli
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [6] Semi-mechanistic PK and target-occupancy modeling to support dose justification for anti-PD-L1 clinical candidate CK-301 (TG-1501) in oncology patients
    Lin, Lin
    Hilbert, James
    Gorelik, Leonid
    Tang, Jian-Ping
    Oliviero, James
    Apgar, Joshua
    Gruenbaum, Lore
    Burke, John
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
1